RemeGen (9995) reported a notable increase in operating revenue for 2025, reaching 3.25 billion renminbi, an 89.36% rise from the previous year. The company’s net profit attributable to owners of the parent surged to 708.52 million renminbi, and net profit after non-recurring gains and losses amounted to 65.06 million renminbi.

Gross profit margins improved significantly, reflecting higher sales of core products telitacicept and disitamab vedotin, as well as efficiency gains from production process refinements. In addition, the exclusive licensing agreement with Vor Biopharma Inc. drove up technology licensing revenue and contributed to lower overseas R&D expenses. These positive factors, along with a decline in the sales expense ratio, helped the company reverse its loss position from the previous year.

Total assets stood at 7.24 billion renminbi at the end of 2025, up 31.65% from the beginning of the period. Owner’s equity attributable to the parent increased by 81.40% to 3.60 billion renminbi, supported by both improved profitability and proceeds from the issuance of 19.00 million H shares in May 2025. As a result, net assets per share attributable to owners of the parent rose to 6.72 renminbi, an 82.11% jump from the start of the year.